Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.54 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.32 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.32 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19405753 | 0.85 | TSHR (0.51) | TSHRSMPD1POLBAPEX1HTT | |
| SCHEMBL19405710 | 0.85 | TSHR (0.51) | TSHRSMPD1POLBAPEX1HTT | |
| SCHEMBL19418243 | 0.83 | TSHR (0.49) | TSHRSMPD1POLBAPEX1HTT | |
| SCHEMBL19417973 | 0.83 | TSHR (0.49) | TSHRSMPD1POLBAPEX1HTT | |
| SCHEMBL19409701 | 0.81 | TSHR (0.57) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL19405762 | 0.81 | TSHR (0.57) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL328746 | 0.81 | TSHR (0.57) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL2996070 | 0.81 | SMPD1 (0.46) | TSHRSMPD1LPAR3LPAR1LPAR2 | |
| SCHEMBL541106 | 0.81 | TSHR (0.47) | TSHRSMPD1POLBAPEX1HTT | |
| SCHEMBL541808 | 0.81 | TSHR (0.47) | TSHRSMPD1POLBAPEX1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10188588-B2 | Acidic hybrid monomers and dental materials based thereon | IVOCLAR VIVADENT AG (LI) | 2019-01-29 | — | — | US | disclosed |
| US-20170281475-A1 | ACIDIC HYBRID MONOMERS AND DENTAL MATERIALS BASED THEREON | IVOCLAR VIVADENT AG (LI) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10188588-B2 | Acidic hybrid monomers and dental materials based thereon | NR1I3, NR1I2, GRIN1 | TSHR 2098/4885SMPD1 4711/4885POLB 2658/4885 |
| US-20170281475-A1 | ACIDIC HYBRID MONOMERS AND DENTAL MATERIALS BASED THEREON | NR1I3, NR1I2, GRIN1 | TSHR 2098/4885SMPD1 4711/4885POLB 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.